Sight Sciences, Inc. (SGHT) — SEC Filings
Sight Sciences, Inc. (SGHT) — 36 SEC filings. Latest: 8-K (Apr 23, 2026). Includes 22 8-K, 5 10-Q, 3 SC 13G/A.
View Sight Sciences, Inc. on SEC EDGAR
Overview
Sight Sciences, Inc. (SGHT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 30, 2026: On March 27, 2026, Sight Sciences, Inc. filed an 8-K report detailing its financial statements and exhibits. The filing includes an iXBRL 8-K document and an exhibit EX-99.1, along with associated XBRL data files. The company's principal executive offices are located at 4040 Campbell Ave, Suite 100,
Sentiment Summary
Across 36 filings, the sentiment breakdown is: 2 bearish, 32 neutral, 2 mixed. The dominant filing sentiment for Sight Sciences, Inc. is neutral.
Filing Type Overview
Sight Sciences, Inc. (SGHT) has filed 22 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 3 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (36)
Risk Profile
Risk Assessment: Of SGHT's 26 recent filings, 1 were flagged as high-risk, 11 as medium-risk, and 14 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $19.906M |
| Net Income | -$8.169M |
| EPS | -$0.15 |
| Debt-to-Equity | 0.62 |
| Cash Position | $92.373M |
| Operating Margin | -39.71% |
| Total Assets | $116.256M |
| Total Debt | $40.069M |
Key Executives
- Jeremy B. Hayden
- Dr. David J. Muller
- Dr. Michael J. Weber
- Dr. Marcella R. Sinibaldi
Industry Context
Sight Sciences operates in the ophthalmic medical device market, focusing on treatments for glaucoma and dry eye disease. The industry is characterized by innovation, significant R&D investment, and a complex regulatory landscape. Key competitors often have established market presence and substantial financial resources, making market share gains challenging.
Top Tags
sec-filing (5) · financials (4) · 8-K (4) · corporate-governance (4) · Medical Devices (3) · financial-reporting (3) · 10-Q (3) · exhibits (2) · Ophthalmology (2) · Dry Eye Disease (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC Accession Number | 0001193125-26-130386 | Unique identifier for the filing |
| Quarterly Revenue | $19.906M | Down from $20.157M in Q3 2024, indicating a slight decline. |
| Quarterly Net Loss | $8.169M | Improved from $11.066M in Q3 2024, showing reduced losses. |
| Nine-Month Net Loss | $34.264M | Improved from $39.661M in the prior nine-month period, reflecting better financial control. |
| Cash and Cash Equivalents | $92.373M | Decreased from $120.357M at year-end 2024, highlighting cash burn. |
| Accumulated Deficit | $380.6M | Indicates significant historical losses since inception. |
| Quarterly Cost of Goods Sold | $2.709M | Reduced from $3.250M in Q3 2024, contributing to gross profit improvement. |
| Quarterly Total Operating Expenses | $25.102M | Decreased from $28.136M in Q3 2024, showing effective cost management. |
| Common Stock Shares Outstanding | 52,871,731 | As of October 31, 2025, indicating dilution from prior periods. |
| SEC File Number | 001-40587 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 80-0625749 | Company's tax identification number. |
| Net Loss | $19.9M | Q2 2025 net loss, a slight improvement from $20.1M in Q2 2024. |
| Net Loss (YTD) | $40.1M | Six months ended June 30, 2025, indicating continued unprofitability. |
| R&D Expenses | $7.5M | Q2 2025 R&D expenses, a decrease from $7.8M in Q2 2024. |
| SG&A Expenses | $30.1M | Q2 2025 SG&A expenses, an increase from $29.7M in Q2 2024. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Sight Sciences, Inc. (SGHT)?
Sight Sciences, Inc. has 36 recent SEC filings from Jan 2024 to Apr 2026, including 22 8-K, 5 10-Q, 3 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SGHT filings?
Across 36 filings, the sentiment breakdown is: 2 bearish, 32 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Sight Sciences, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Sight Sciences, Inc. (SGHT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Sight Sciences, Inc.?
Key financial highlights from Sight Sciences, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SGHT?
The investment thesis for SGHT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Sight Sciences, Inc.?
Key executives identified across Sight Sciences, Inc.'s filings include Jeremy B. Hayden, Dr. David J. Muller, Dr. Michael J. Weber, Dr. Marcella R. Sinibaldi.
What are the main risk factors for Sight Sciences, Inc. stock?
Of SGHT's 26 assessed filings, 1 were flagged high-risk, 11 medium-risk, and 14 low-risk.
What are recent predictions and forward guidance from Sight Sciences, Inc.?
Forward guidance and predictions for Sight Sciences, Inc. are extracted from SEC filings as they are enriched.